Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:42:22 EDT Sun 22 Jun 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:SPRY
- ARS PHARMACEUTICALS INC -
Website unknown - click to update
10:42:22 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
SPRY
- Q
0.6
15.00
·
16.25
0.2
15.80
-0.11
-0.7
1,338.1
20,541
10,838
15.99
16.11
15.45
18.51 7.55
17:43:17
May 27
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 10838
More trades...
Time ET
Ex
Price
Change
Volume
17:43:17
Q
15.8399
-0.0701
500
16:20:00
Q
15.80
-0.11
958
16:14:55
Q
15.80
-0.11
8,198
16:11:38
Q
15.80
-0.11
1,918
16:08:16
Q
15.47
-0.44
20
16:04:20
Q
15.80
-0.11
124
16:04:15
Q
15.80
-0.11
1
16:04:15
Q
15.80
-0.11
1
16:04:06
Q
15.80
-0.11
521
16:04:02
Q
15.80
-0.11
66
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-05-27 08:01
U:SPRY
News Release
200
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-05-14 07:00
U:SPRY
News Release
200
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy(TM) (epinephrine nasal spray)
2025-05-07 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals' neffy(TM) (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-05-05 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
2025-05-02 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy(TM) (epinephrine nasal spray) to Additional U.S. Pediatricians
2025-03-20 07:00
U:SPRY
News Release
200
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-05 16:10
U:SPRY
News Release
200
ARS Pharmaceuticals Announces FDA Approval of neffy(TM) 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-03-03 16:35
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
2025-02-20 19:02
U:SPRY
News Release
200
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy(TM) (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
2025-02-18 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy(TM) (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
2025-02-05 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
2025-01-21 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
2025-01-13 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(TM) (epinephrine nasal spray)
2025-01-06 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Files for Approval of neffy(TM) in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S
2024-12-19 17:25
U:SPRY
News Release
200
ARS Pharmaceuticals Announces neffy(TM) (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
2024-12-18 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-12 14:33
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Filings for Approval of neffy(TM) in China, Japan and Australia
2024-12-04 08:00
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
2024-11-13 06:30
U:SPRY
News Release
200
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-11-11 07:00
U:SPRY
News Release
200
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy(TM) in Europe, Canada and Other Geographies Outside the United States